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Abstract
Sufficient exercise and sleep, a balanced diet, moderate alcohol consumption and a good approach to handle stress have 
been known as lifestyles that protect health and longevity since the Middle Age. This traditional prevention quintet, turned 
into a sextet by smoking cessation, has been the basis of the “preventive personality” that formed in the twentieth century. 
Recent analyses of big data sets including genomic and physiological measurements have unleashed novel opportunities to 
estimate individual health risks with unprecedented accuracy, allowing to target preventive interventions to persons at high 
risk and at the same time to spare those in whom preventive measures may not be needed or even be harmful. To fully grasp 
these opportunities for modern preventive medicine, the established healthy life styles require supplementation by stratified 
prevention. The opportunities of these developments for life and health contrast with justified concerns: A “surveillance 
society”, able to predict individual behaviour based on big data, threatens individual freedom and jeopardises equality. 
Social insurance law and the new German Disease Prevention Act (Präventionsgesetz) rightly stress the need for research 
to underpin stratified prevention which is accessible to all, ethical, effective, and evidence based. An ethical and acceptable 
development of stratified prevention needs to start with autonomous individuals who control and understand all information 
pertaining to their health. This creates a mandate for lifelong health education, enabled in an individualised form by digital 
technology. Stratified prevention furthermore requires the evidence-based development of a new taxonomy of cardiovascular 
diseases that reflects disease mechanisms. Such interdisciplinary research needs broad support from society and a better use 
of biosamples and data sets within an updated research governance framework.
Keywords Genomics · Prevention · Heart failure · Atrial fibrillation · Stratified medicine · Personalised medicine · Payor · 
Health economics
From the “sextet of prevention” 
to the development of stratified prevention
Interactions between genetic susceptibility, acquired behav-
iour, formative life events and environmental factors deter-
mine the development of several chronic diseases, includ-
ing cardiovascular conditions. The increasing availability of 
large data sets that integrate genomic information, specific 
organ function, and behavioural patterns in populations 
allows to precisely estimate individual risks of common 
diseases and their drivers more precisely. Such analyses 
enable individualised treatment of patients and a stratifica-
tion of preventive interventions [1, 2]. Stratified prevention 
has tremendous potential for the prevention of cardiovascu-
lar diseases such as coronary heart disease, heart failure or 
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atrial fibrillation, which develop slowly and chronically. The 
starting point of stratified prevention is the implementation 
of tried-and-tested truths: healthy life styles, described since 
the Middle Ages and later supplemented by smoking cessa-
tion, are supported by a large evidence base (textbox) [3].
The sextet of preventive life styles
sufficient physical activity
a balanced diet
sufficient sleep
moderate alcohol consumption or abstinence
avoiding or compensating for stress
not smoking
Society and governments have a duty to support imple-
mentation of healthy life styles and to provide a healthy 
environment, e.g. clean water, sufficient nutrition, access to 
essential vaccinations, screening visits for children and preg-
nant women, and possibly a mandate to provide access to 
clean air. There is an undisputed requirement to provide such 
a healthy environment. In addition, adequate information 
about the impact of everyday decisions on health is within 
the remit of a democratic society, e.g. as written and colour-
coded warnings on foodstuffs [4]. A free and democratic 
society also limits the power of the state to subconsciously 
encourage healthy behaviour without enacting provisions 
of regulatory law (“nudging”) [5]. While “nudging” may 
help to encourage decisions and behaviour that protects 
health, such interventions are only acceptable when they are 
planned and conducted transparently by a democratic state, 
respecting citizens’ rights and freedom [5]. As such, legal 
stipulations to locate sweets and alcohol in supermarkets in 
places that disincentivise their purchase may be acceptable. 
Exaggerations that are not in line with the rule of law would 
be subliminal advertising or other manipulative activities by 
public authorities promoting a healthier lifestyle, or the his-
torical example—under administrative law—of the “health 
confession” proposed by Leibniz [6, 7].
The “preventive self”
Improved hygiene and nutrition, the development of anti-
biotics, and the introduction of immunisation programmes 
in the nineteenth and twentieth century allowed a quantum 
leap in life expectancy and a shift in the spectrum of dis-
eases and causes of death (“epidemiological transition”, [8]). 
Cancer and cardiovascular diseases are now the most com-
mon causes of death in industrialised countries. Reflecting 
this basic change, greater attention is paid to maintaining 
individual health: society is developing and demanding a 
“preventive self” [9], and health care provides advanced pre-
ventive treatments to prolong life [10–13]. Even though the 
societal consequences of this trend require further analyses, 
the goal of a longer, healthier life, and hence also a right to 
know about potential hazards, is worthy of support. Having 
said that, knowledge of health risks and preventive interven-
tions to reduce that risk does not create a normative conse-
quence obliging individuals to implement such measures.
Health and disease are a continuum whose extremes are 
easily defined—fully healthy or definitely ill—while the 
transitions from “quite healthy” to “slightly unwell” are 
often more difficult to determine. This has been described 
over more than 40 years of salutogenesis research, which 
was triggered amongst other things by the WHO’s broad 
definition of health. A disease state in this continuum is 
defined by biological causes of disease and quantifiable dis-
ease consequences, but also by the subjective disease experi-
ence and its social perception. The simple healthy life style 
recommendations discussed above (textbox) already iden-
tify factors supporting health and risk factors for disease. 
Encouraging such behaviour will maintain or improve health 
of an individual. Novel information, e.g. on predisposition 
to certain diseases, allow a more precise estimation of risks 
to health. This information further transforms the dichotomy 
between “healthy” and “ill” to a continuous scale on which 
people are assigned a calculable risk of physical or mental 
harm. Knowing one’s own risk or that of others opens up 
opportunities for personalised prevention, but may also have 
negative consequences if fear and uncertainty, or a threat of 
unequal treatment, are the consequence.
Health information as a central tool 
to promote prevention in a free society
The implementation of evidence-based life styles (textbox) 
is often difficult. Barriers to implementation include a lack 
of motivation to alter behaviour for distant and abstract ben-
efits, a lack of information and education, and adherence 
to socially encouraged or acquired behaviours and habits 
encouraged by family, peer group, and the broader social 
setting. This social environment often maintains or even 
amplifies unhealthy behaviour [14]. Competing interests 
also support unhealthy behaviour, e.g. in the form of adver-
tising for consumer goods, and increasingly via digital and 
“social” media. Everyone has a right to accurate informa-
tion and knowledge about prevention to enable autonomous, 
informed decisions on prevention respecting individual 
rights. Is the resulting information mandate currently satis-
fied? There seems to be further need for effective and contin-
ued information on how to best maintain health by life styles, 
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linked to social consensus that everyone bears responsibility 
for their own health. The experience to date suggests that 
suppressing (mis)information (for instance by restricting 
advertising) is less useful to enable autonomous, informed 
decisions on prevention than providing accurate information.
The conference of Ministers of Education and Culture 
adopted a recommendation on “Health education at school” 
in 1979, and updated it to a “Recommendation on health 
promotion and disease prevention at school” in 2012. But 
information about healthy behaviour needs to be a lifelong 
process, as behaviour is shaped throughout life by cul-
tural and societal factors. Digital technologies (the Inter-
net, smartphones, social media, the digital “surveying of 
the self”), which are part and parcel of modern everyday 
life, have the potential to reach populations that are less 
receptive to current means of health information. In addi-
tion, such technology allows a multi-channel architecture 
of communication incorporating individualised processing, 
enables context-dependent assistance including integration 
of bio-feedback from smartphones or fitness trackers [14], 
and provides feedback on the effects of technology-based 
information campaigns. Such health information needs to 
be credible and quality assured, thus calling for continuous 
update based on novel evidence [14].
Stratified cardiovascular medicine
Prevention and management of cardiovascular diseases 
has markedly improved in the last decades, relying on 
evidence-based interventions targeting major mechanisms 
of heart disease. Consequently, cardiovascular mortality 
is lower now than it was 20 years ago. Progress has also 
been made when it comes to describing disease mechanisms 
and developing and validating targeted therapies of these 
mechanisms in controlled clinical studies. This is one of the 
reasons why life expectancy increased in Germany in recent 
years [15]. One-half of this gain in life years is attributable 
to cardiovascular prevention, and roughly the other half to 
improvements in the treatment of patients with cardiovas-
cular diseases, with smooth transitions between prevention 
and therapy (see Fig. 1, upper panel, for current delivery of 
cardiovascular prevention and therapy in Germany). These 
successes have however triggered a “spiral of evidence”, 
rendering cardiovascular medicine a victim of its own suc-
cess [15]: ever larger studies are needed to prove the addi-
tional benefit of new interventions and treatments, markedly 
increasing the resources needed to develop new treatments 
to market. While patient safety justifies such approaches, the 
effort involved in obtaining approval for new forms of treat-
ment is threatening the development of new cardiovascular 
therapies [16]. In addition, current disease classifications 
and regulatory processes incentivise to test and approve 
new treatments in large patient groups, including those in 
whom the new therapy does not appear ideal. This lack of 
appropriate patient stratification is considered as one of 
the drivers for the “late-phase failures” in the development 
of cardiovascular medicines [16]. In view of the consider-
able remaining cardiovascular morbidity and mortality in 
Europe, these developments need addressing. Particularly, 
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Fig. 1  The changing nature of care. a Current provision of access to 
information on healthy lifestyles and access to healthcare. The state 
provides support to maintain health, e.g. a healthy and safe environ-
ment and information about healthy lifestyles. The state also funds (or 
part-funds) access to healthcare for those who suffer from diseases. 
b Our vision for an interdisciplinary approach to enable stratified 
prevention and management of health and disease. Here, the state 
provides stratified support to maintain and regain health, including 
a secure environment to share information about health and health 
risks. This environment supports the development and practice strati-
fied prevention and disease management
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pathophysiological heterogeneity within common cardiovas-
cular diseases has led to a demand for a new disease tax-
onomy that better reflects disease mechanisms, exemplified 
for atrial fibrillation in [17]. Disease drivers can be based 
on genomic and biomedical differences, but also rooted in 
different social contexts. Describing and classifying these 
drivers has the potential to unleash stratified prevention and 
management. This requires flexible thinking and interdisci-
plinary action in academia, in the cardiovascular drug and 
device industry, with regulators and with research funders. 
The European Medicines Agency (EMA) and the Food and 
Drug Administration (FDA) have already started adjusting 
the requirements for approval of new medicines. The sci-
ence-based approach to knowledge generation—proof of the 
association of characteristics with manifestations of a dis-
ease, identification of disease mechanisms and subsequently 
controlled intervention studies—is still required to validate 
the safety and effectiveness of such stratified prevention and 
management approaches.
The institutional framework for prevention 
in Germany
Medical prevention is taking place at the crossroads between 
self-determination and heteronomy, of freedom and obliga-
tion to take preventive action. In a free state based on the 
rule of law, this tension is largely resolved via the fundamen-
tal human rights. Individual freedom allows each person to 
decide whether and how to participate in prevention. State 
coercion to engage in prevention violates these fundamental 
rights, and is thus unconstitutional. To protect these funda-
mental rights, the state also has an obligation to foil coer-
cion imposed by private entities, e.g. insurance companies 
or employers. Health, on the other hand, has a transcendental 
significance as it is a prerequisite for a self-determined life. 
Hence, the state also has a constitutional mandate to promote 
and protect the health of the individual through information, 
education and provision of health care for those suffering 
from disease. These measures can even be required to allow 
individuals to exercise autonomous prevention, or to decide 
against it.
A variety of players with their respective specific respon-
sibilities, such as the Federal Centre for Health Education 
(Bundeszentrale für gesundheitliche Aufklärung, a specialist 
authority within the remit of the Federal Ministry of Health), 
the public health service, general practitioners and special-
ist physicians such as cardiologists, professional organisa-
tions, associations and initiatives, as well as the institutions 
of statutory health, long-term care, accident and pension 
insurance, seek to perform the constitutional broad educa-
tional and information mandate. This reflects the character-
istic federal diversity of the German healthcare system. The 
Disease Prevention Act (PrävG) obliges the social insurance 
funding institutions within the healthcare system, and the 
health insurance funds in particular, to develop a “National 
Prevention Strategy” on which large numbers of agencies 
collaborate at Federal, Bundesland (federal state), and local 
authority level. In 2016, the National Prevention Confer-
ence adopted for the first time standard national federal 
framework recommendations spanning funding institutions 
on health promotion and companies (Fig. 1). The health 
insurance funds’ recently established Innovation Fund also 
enables the implementation and evaluation of new preven-
tion methods. Even if in particular the State and the health 
insurance funds are promoting this development, it is unclear 
whether better prevention of chronic diseases will reduce or 
increase costs and expenditure in the healthcare system [18]. 
At any rate, such measures derive their justification first and 
foremost from their benefit for the population, and not from 
economic considerations.
Reflecting on the development of stratified medicine 
and—unconsciously in some cases—also to evolving con-
cepts for stratified prevention, the legal system then stresses 
existing research requirements if preventive model projects 
are planned. Primary prevention, secondary prevention, as 
well as tertiary prevention, are legally acknowledged in addi-
tion to the general promotion of health. Apart from a small 
number of exceptions such as protective vaccinations, the 
content of “[p]rimary prevention and health promotion” [the 
title of section 20 of Book V of the German Social Code 
(SGB V)] is not legally defined. The concrete measures are 
defined by individual health insurers (cf. section 20 subsec-
tion (1) sentence 1 of Book V of the Social Code). Many 
projects so far have been pilot projects (“Modellvorhaben”, 
section 20g of Book V of the Social Code) which aim to 
generate the required knowledge for effective prevention, 
including early diagnosis and specific targeting of popula-
tions at risk. Unfortunately, most current projects do not 
have sufficient scientific input and guidance in their design 
and are underpowered, compromising the generation of 
credible evidence. For the first time, the Innovation Fund 
implements an application and evaluation procedure prior to 
initiation. This may fill the gaps between the current provi-
sion of general information and education and the desired 
targeted prevention of cardiovascular diseases in at-risk 
populations.
The deep and detailed information required to identify 
individuals who will benefit from stratified prevention bears 
the inherent threat of a “brave new world”: access to big data 
sets could pave the way for a surveillance state that lacks 
privacy. This may even allow to predict the behaviour of 
individuals based on analysis of big data sets, opening the 
door for manipulation by the state or by other interested par-
ties [1, 2]. Furthermore, cumulative restrictions may threaten 
individual freedom and integrity, e.g. by sanctioning the 
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omission of useful preventive measures or when the right 
not to know is ignored, which may also promote health. Fur-
thermore, programmes aiming at early diagnosis can lead to 
misdiagnoses and over treatment with a potential to waste 
resources and/or to harm. Insights into information identify-
ing specific health risks which form the basis for personal-
ised prevention, e.g. behavioural or genomic data, need to 
be aligned with the constitutional entitlement to equal rights 
and obligations for all citizens. State intervention may at 
times be needed in extremis to maintain equality. The legal 
starting point and the guiding principle for this harmonisa-
tion is the informed, autonomous, free (Fig. 1).
Legal restrictions and the need to adapt 
research consent procedures
Better information, the pilot projects discussed in section V, 
the prevention strategy of the new Disease Prevention Act, 
and the opportunities and risks of stratified prevention all 
underpin a broad interdisciplinary research mandate. Ethi-
cal research relies on transparent procedures and consent 
of participating individuals. The subject’s consent to take 
part in a research project is a central expression of his or 
her self-determination, which is guaranteed in many ways 
at the level of fundamental rights and human rights [Art. 2 
and Art. 1 of the Basic Law (GG), Art. 3§ 2 of the Euro-
pean Convention on Human Rights (ECHR), Art. 5 of the 
Convention of the Council of Europe on Human Rights and 
Biomedicine]. At difference to consent to a medical inter-
vention, the health benefit for the subject of a research pro-
ject is uncertain. Furthermore, the essence of research is 
that it is not known in advance what results will be achieved. 
Moreover, new scientific knowledge may necessitate the re-
analysis of existing data for a different research purpose 
than was originally planned. The advancing research may 
hence make it appear expedient to re-examine existing data 
sets or to alter the originally planned course of the research, 
including the methods that had been considered. This par-
ticularly applies today given the furious pace of development 
in stratified medicine. Such additions to or deviations from 
the original research plan are however often not covered by 
current research procedures, and would frequently require 
once more informing the patient or subject and obtaining 
their consent, which is almost always impossible, particu-
larly with large volumes of data. What is therefore needed 
is a new general consent enabling the subject to consent to 
research as a process, including consent to the re-analysis 
and re-examination of data and biosamples which were col-
lected during a research project. Such a consent should be 
comprehensible, targeted and layered. The layering will 
enable individuals to choose between general or partial con-
sent to the research plans according to a pre-defined scheme, 
which can make provision for exclusions. This general con-
sent trusts the researchers and research institutions. Hence, 
research institutions need to provide sufficient governance 
for ongoing research projects (See "Governance of strati-
fied research projects and biobanks"). Participants in a 
research study are particularly worthy of protection since an 
individual health benefit is frequently unable to compensate 
for participation in the test. The protection of the subject and 
the open-ended nature of the research aims must be reflected 
in the consent form. The general research regulations (Good 
Clinical Practice—GCP, International Council for Harmo-
nisation of Technical Requirements for Pharmaceuticals for 
Human Use—ICH) remain in force. This means
– that the subject is able to consent in general terms to take 
part in a research project whose aims and goals can only 
be partially defined at the time of consenting,
– that the re-use of data by third parties requires separate 
consent, which can be obtained in advance,
– and that information relating to third parties (gene analy-
ses) may only be passed on if the interests of the subjects 
are taken into account (andwith the consent of all con-
cerned).
Given the general consent to take part in the study and 
the measures which this entails, oral and written informa-
tion is to be limited to the essentials of the study, such as the 
research aims, the general process, the foreseeable risks and 
the general use of data and biosamples. The consent form 
needs to enable the subject to understand and consent to the 
process. Superfluous, overly-detailed information sheets and 
consent forms are to be avoided here.
Governance of stratified research projects 
and biobanks
The undefined outcomes of biomedical research at the outset 
require a defined governance of research projects oversee-
ing research conduct and communication of findings back 
to individuals and to the wider research community. Such 
governance must respect citizens’ right of personality (Art. 
2§ 1 of the Basic Law, Art. 7 et seq. of the European Charter 
on Human Rights and Art. 8 ECHR) and against genetic 
discrimination (Art. 3§ 1 of the Basic Law and Art. 21 of 
the European Charter on Human Rights), whilst on the other 
hand promoting biomedical research (Art. 5§ 3 sentence 1 
of the Basic Law and Art. 13 of the European Charter on 
Human Rights), particularly with a view to individual and 
public health (Art. 2§ 2 sentence 1 of the Basic Law and 
Art. 35 of the European Charter on Human Rights). The 
starting point for the regulation of biobanks in Germany is 
data protection law [section 2 subsection (2) No. 1 of the 
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Genetic Diagnostics Act (Gendiagnostikgesetz GenDG)]. 
Such “governance”, which is primarily covered by data pro-
tection law, however fails to do justice to the requirements 
of a nuanced research infrastructure: first with respect to the 
altruistic donations made by many thousands of citizens, 
and second with a view to their function, namely to promote 
individual and public health. This calls for a dynamic regula-
tory approach, which effectively protects the donors’ right of 
self-determination, guarantees biobank confidentiality, regu-
lates biobanks’ establishment and operation, rights of access 
and monitoring, as well as providing for rights to refuse to 
testify under criminal law [18]. The more far-ranging regula-
tory requirement can be illustrated by taking donors’ right of 
self-determination as an example: as a matter of principle, 
the current understanding is that a donation to a biobank 
must be consented for a specific research project. This how-
ever disproportionately restricts the potential for research 
with regard to future scientific questions which cannot be 
predicted at the time of consent. A biobank only does justice 
to its function as a research infrastructure when donations 
can also be given “for science” as a whole. It is not expedi-
ent here to prohibit generalised consent by referring to data 
protection law. Many participants in research projects and 
biobanks are motivated by a general wish to “help research”. 
The general consent corresponding to this wish should be 
legally enclosed by formal procedures and substantive stand-
ards (“governance”). A legislature that accompanies cur-
rent developments in research can inspire citizens’ legally 
justified confidence that their generalised consent will be 
reflected in responsible research. Research sponsors need to 
develop research governance structures that are effective and 
research friendly, and which safeguard fundamental rights, 
in cooperation with ethics commissions, state supervision, 
and data protection authorities.
Interdisciplinary research mandate 
to underpin stratified prevention
It is well established that cardiovascular health can be pro-
tected and maintained by getting enough exercise and sleep, 
a balanced diet, moderate alcohol consumption, not smok-
ing, and suitably dealing with stress (textbox). Research into 
stratified interventions to widen these healthy behaviours can 
help to improve cardiovascular health, especially in socially 
and otherwise defined “areas alienated from prevention”. 
The law here principally focuses on information to enable 
the balancing act typifying prevention to be successful: 
while preserving autonomy of each individual, the mandate 
to protect and further health should be fulfilled—resulting in 
a mandate for lifelong health education. Digital technology 
permits a perhaps decisive step towards easily accessible, 
targeted, context-independent health information which can 
then also be evaluated and which could also reach groups 
of the population which are less willing to take up healthy 
life styles.
Promotion of healthy lifestyles already blurs the bound-
ary between disease and health, as individuals who are 
not “ill” are asked to change their behaviour to maintain 
their health and are placed on a health risk scale. These 
uncertainties are intensified by stratified prevention: large 
and deep biomedical datasets and physiological measure-
ments will allow to predict individual health risks in the 
future, resulting in tailored recommendations for pre-
ventive interventions. These insights offer tremendous 
opportunities to better maintain and protect cardiovascular 
health in specific individuals at high risk. The stratified 
nature of such interventions requires adjustments to the 
paradigm of large clinical trials to evaluate novel inter-
ventions, calling for innovative ways to evaluate stratified 
preventions, similar to the innovative ways that have been 
outlined for the approval of novel, stratified treatments. 
As a reaction to the development of stratified medicine 
and—unconsciously in some instances—also more precise 
prevention, the legal system rightly stresses the general 
information mandate, but then also the need for interdisci-
plinary research, if preventive model projects are provided 
for. It is uncertain how stratified prevention will affect the 
cost of health care: the potential to save cost by avoiding 
chronic diseases may be offset by the cost of treatment 
across a longer life. As maintaining health and prevent-
ing disease is primarily intended to sustainably serve the 
health of those concerned, the economic impact of per-
sonalised prevention can be measured as the concept is 
being developed.
Stratified prevention offers immense opportunities to pre-
vent diseases in a more effective, lower-risk manner. The 
necessary interdisciplinary research must devote itself to 
these elementary goals, but must also address the dangers 
and fears associated with precise risk prediction. The fears 
associated with a society formed by predictable individu-
als are not entirely unfounded, and difficult questions arise 
regarding equal opportunities or measures which as a rule 
make sense medically, but which may endanger health in 
individual cases. The goal is to develop stratified preven-
tion that is ethical, effective, evidence-based and in con-
formity with fundamental rights, and to make it generally 
accessible. Interdisciplinary governance of the development 
of stratified prevention can mitigate these risks to indi-
vidual freedom while leveraging the potential of stratified 
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prevention for the cardiovascular health of populations and 
individuals.
Summary of the main recommendations of the workshop 
in Augsburg
Stratified prevention has immense potential to enhance 
cardiovascular well-being.
An ethical and acceptable development of stratified pre-
vention needs to start with autonomous individuals who 
control and understand all information pertaining to their 
health. This creates a mandate for lifelong health educa-
tion, enabled in an individualised form by digital technol-
ogy for governments, but also for practising physicians.
Stratified approaches to cardiovascular medicine need to 
be evaluated with the same rigour as current evidence-
based cardiovascular medicine, starting with the develop-
ment of a new taxonomy of cardiovascular diseases that 
reflects disease mechanisms.
Interdisciplinary research into stratified prevention needs 
broad support from society and a better use of biosamples 
and data sets.
Current research governance should be amended to ena-
ble research volunteers to donate their data and biosam-
ples to science (including stratified medicine).
Governments and health care systems need to develop 
a framework to provide protected and governed access 
to the necessary information to deliver stratified preven-
tion. The Präventionsgesetz is a basis to develop such a 
framework in Germany.
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